| Novartis Pharma Schweiz AG - Jakavi 5 mg/ml, Lösung zum Einnehmen | | 69722 | | 01 | | Jakavi 5 mg/ml | | Lösung zum Einnehmen | | L01EJ01 | | Ruxolitinib | | 27.03.2025 | | |
| | Composition | | ruxolitinibum 5 mg ut ruxolitinibi phosphas, propylenglycolum 150.0 mg, E 218 1.2 mg, propylis parahydroxybenzoas 0.4 mg, sucralosum, acidum citricum, aromatica (Erdbeer), aqua purificata, ad solutionem pro 1 ml. | | Packungsbestandteile | | Solution (oral) | | | | | | Active Agent | Dose |
|---|
| Ruxolitinibum | 5 mg/ml |
| | | | Inactive agents | Dose | additional_information |
|---|
| Citric Acid | | | | Aqua Purificata | | | | Aromatica (Erdbeer) | | | | E 218 | 1.2 mg/ml | conserv. | | Propylenglycol | 150 mg/ml | | | Propylis Parahydroxybenzoas | 0.4 mg/ml | | | Sucralosum | | |
|
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | 60 ml | PR | PR | A | | No |
|
|
